Loading
Orasure Technologies Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 May 2026.
Orasure Technologies Inc: what insiders have been doing
Every trade that managers of Orasure Technologies Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Orasure Technologies Inc logged 21 filings by 9 insiders.
Every open-market trade in the period is a purchase: 6 purchases worth €346k, from 4 insiders, and not a single sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The largest single trade was a purchase of €82k by McGrath Kenneth J, published on 23 March 2026. Those buying include 2 senior executives, 1 finance chief and 1 chief executive.
For context, the typical company on the same exchange (median of 5,814 companies) published 19 filings over the same period, against 21 filings here. Looking back to 2016, when coverage begins, insiders filed 17 purchases and no sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 115.0 m USD and net income at -68.7 m USD.
In all, 4 purchases were made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 14 May 2026, which is 157 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
158
Thresholds
n/a
Buy Volume
€2M
17 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleManner Carrie Eglinton4 buys
Kenneth J. McGrath3 buys
Nancy J. Gagliano2 buys
John P. Kenny1 buy
Lelio Marmora1 buy
Steven Kyle Boyd1 buy
Since the insiders bought
- +27.0%Entry US$3.00 · Close 15 Oct 2026 US$3.81
- +35.9%Entry US$3.06 · Close at T+90 US$4.16
- +35.9%Entry US$3.06 · Close at T+90 US$4.16
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,671 of 24,148 companies
17.6
score / 100
Value9
Quality26
FCF yld-21%
Earn yld-28%
EV/EBITDA·
ROE-14%
Gross mgn42%
Net mgn-60%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.71
Analyst consensus
1 analysts2.00/5
US$4.00Target US$4.00(+8%)US$4.00
Income statement
RevenueUS$115M
Gross profitUS$48.2M42% margin
EBITDA-US$58.2M-51% margin
Net income-US$68.7M-43.7% margin
Valuation
PER (forward)-5.6x
P/Book0.8x
Beta1.02
Balance sheet & cash
Market capUS$255.9M
Total debtUS$13.2M
Free Cash Flow-US$53.2M
Debt / Equity4%
Profitability & ownership
ROE-14.1%
ROA-11.0%
% insiders6.5%
% institutions89.0%
Last declaration on 1 October 2026
Declarations158 total
4,797 shares@ US$3.880.0070% mcap17.4% of flowCommon StockSEC:0001470831-26-000918:0
5,116 shares@ US$3.42750.0063% mcap21.3% of flowCommon StockSEC:0001470831-26-000880:0
3,666 sharesCommon StockSEC:0001470831-26-000683:0
46,106 shares0Common StockSEC:0001470831-26-000515:0
46,106 shares0Common StockSEC:0001470831-26-000516:0
33,661 shares0Common StockSEC:0001470831-26-000442:0
22,888 shares@ US$3.020.029% mcap74.2% of flowCommon StockSEC:0001470831-26-000437:0
21,305 shares@ US$3.020.027% mcap34.0% of flowCommon StockSEC:0001470831-26-000436:0
28,406 shares@ US$3.020.035% mcap38.1% of flowCommon StockSEC:0001470831-26-000438:0
25,000 shares@ US$2.980.031% mcap81.9% of flowCommon StockSEC:0001470831-26-000443:0
Canonical exit: 10 Aug 2026 (T+90)
5,246 shares@ US$3.097518.1% of flowCommon StockSEC:0001116463-26-000019:0
32,300 shares@ US$2.928848.4% of flowCommon StockSEC:0001470831-26-000311:0
Canonical exit: 18 Jun 2026 (T+90)
32,300 shares@ US$2.92872.1% of flowCommon StockSEC:0001470831-26-000310:0
Canonical exit: 18 Jun 2026 (T+90)
14,183 shares0Common StockSEC:0001470831-26-000294:0
22,021 shares@ US$2.998533.9% of flowCommon StockSEC:0001470831-26-000282:0
Canonical exit: 11 Jun 2026 (T+90)
22,022 shares@ US$2.99851.5% of flowCommon StockSEC:0001470831-26-000281:0
Canonical exit: 11 Jun 2026 (T+90)
26,814 shares0Common StockSEC:0001470831-26-000242:0
129,032 shares0Common StockSEC:0001470831-26-000241:0
10,286 shares@ US$2.4630.4% of flowCommon StockSEC:0001470831-25-000448:0
34,632 shares0Common StockSEC:0001470831-25-000380:0
2,100 shares@ US$2.37232.7% of flowCommon StockSEC:0001470831-25-000377:0
Canonical exit: 26 Feb 2026 (T+90)
6,118 shares@ US$3.26924.0% of flowCommon StockSEC:0001470831-25-000232:0
12,524 shares@ US$2.7817.7% of flowCommon StockSEC:0001062993-25-014059:0
7,317 shares@ US$3.20525.8% of flowCommon StockSEC:0001062993-25-013517:0
6,657 shares@ US$3.008224.3% of flowCommon StockSEC:0001062993-25-012140:0
25 of 158 declarations
About Orasure Technologies Inc
OraSure Technologies Inc. (NASDAQ: OSUR) is a U.S.-based diagnostics and sample-collection company headquartered in Bethlehem, Pennsylvania, United States. Founded in 1987 as SolarCare, the company adopted the OraSure Technologies name in 2000 when it entered the public markets. For French-speaking investors in Europe, OraSure can be viewed as a specialized healthcare tools company focused on decentralized testing, meaning diagnostics designed for use at the point of care, at home, or in near-patient settings.
The business is organized around two core pillars: diagnostics and sample management solutions. In diagnostics, OraSure sells rapid tests and related devices across several clinical areas, including HIV, hepatitis C, COVID-19, syphilis, sickle cell disease, and historically Ebola. In sample management, the company provides collection and stabilization technologies that preserve DNA and RNA across multiple sample types such as saliva, oral fluid, urine, skin cells, blood, and stool. This platform is strategically important because it broadens the company’s reach into genomics research, laboratory workflows, and specialized clinical applications.
Read moreShow less
From a competitive standpoint, OraSure holds a niche position in rapid diagnostics and specimen collection, with a well-recognized brand franchise around OraQuick and its collection technologies. However, the company operates in a crowded and heavily regulated market, where reimbursement dynamics, public-health funding, and regulatory approvals materially influence demand. Recent results underline that the business has been transitioning away from the pandemic-era COVID revenue spike; at the same time, the underlying core business has remained relatively more stable, with diagnostics showing year-over-year growth in early 2025 even as total revenue declined because of the sharp drop in COVID-related sales.
Geographically, OraSure is anchored in Bethlehem, Pennsylvania, with additional operations through DNA Genotek in Ottawa, Canada, Sherlock Biosciences in the U.S. and the U.K., and BioMedomics in North Carolina. This footprint supports both product development and international commercialization. Recent company updates in 2025 and early 2026 highlighted management’s push to reaccelerate growth through new product milestones, including a rapid molecular self-test for Chlamydia and Gonorrhoeae and the Colli-Pee™ at-home urine collection device for sexually transmitted infection testing. Management also referenced a $40 million share repurchase program, which signals a willingness to return capital while execution improves.
Overall, OraSure Technologies is a small-cap U.S. healthcare diagnostics name listed on the NASDAQ, with meaningful exposure to innovation, regulatory timing, and post-pandemic normalization. For investors monitoring SEC Form 4 insider activity, the stock can be viewed as a catalyst-driven diagnostics platform with both operational leverage and elevated execution risk.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
